Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Reasons for discontinuation of treatment with bortezomib and dexamethasone (nā€‰=ā€‰40) and numbers of patients, which had conventional therapy in patients who discontinued bortezomib and dexamethasone with PD (nā€‰=ā€‰27)

From: Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival

1) No. of patients who discontinued therapy n (%) 40 (100)
- CR with autologous stem cell transplantation 5 (12.5)
- CR without stem cell transplantation 1 (2.5)
- PD 27 (67.5)
- toxicity 1 (2.5)
- other reasons 6 (15.0)
2) No. of patients who had conventional chemotherapy in 27 patients who discontinued bortezomib and dexamethasone with PD n (%) 27 (100)
- conventional chemotherapy with autologous stem cell transplantation 6 (22.2)
- conventional chemotherapy with autologous stem cell transplantation and radiotherapy 1 (3.7)
- conventional chemotherapy with radiotherapy 1 (3.7)
- conventional chemotherapy alone 12 (44.4)
- no additional therapy 7 (25.9)
  1. CR: complete response; PD: progressive disease.